Doctor of Science

Preterm Births Linked to 'Hormone Disruptor' Chemicals May Cost United States Billions

Retrieved on: 
Tuesday, February 6, 2024
ECHO, University, Columbia University, NYU, Cosmetics, Phthalate, Bangladesh Technical Education Board, Champaign–Urbana metropolitan area, Wayne State University, Lancet, NYU Langone Health, Food, National Institutes of Health, DEHP, MPH, Emory University, Woman, Johns Hopkins University, Population health, MPP, Blood, DIDP, Northeastern University, Infant, Risk, Doctor of Philosophy, Rutgers University, Cancer, Gestational age, Triangle Park (Quezon City), Racism, Mother, Research, Obesity, Preterm birth, RTI International, The Lancet, Pregnancy, Doctor of Science, Dartmouth College, Diabetes, Pennsylvania State University, Urine, Hormone, Achievement Medal, Pediatrics, Dietary supplement

Then, the team looked for associations between these metabolite levels and preterm births.

Key Points: 
  • Then, the team looked for associations between these metabolite levels and preterm births.
  • "Otherwise, investigators are likely going to find the same study results in another few years about the next group of chemicals used as replacements."
  • California, among a few states, has banned some use of phthalates in consumer products, as have European Union member states.
  • Trasande cautions that further research is needed to better understand the specific mechanisms behind the link between phthalate exposure and preterm birth.

Groundbreaking Study Demonstrates 20-Year Remission in Pemphigus Vulgaris Patients Using IVIg Therapy

Retrieved on: 
Wednesday, January 31, 2024
Ahmad, Research, Science, Pemphigus vulgaris, National academy, Patient, Avicenna, Immune tolerance, Doctor of Science, MPA, PNAS, FRCP, Immunoglobulin therapy, DDF, Admiration

Researchers from Tufts University School of Medicine (Boston, MA) and Sorbonne Université (Paris, France) have demonstrated a remarkable 20-year clinical and serological remission in patients using a defined protocol of intravenous immunoglobulin (IVIg) therapy.

Key Points: 
  • Researchers from Tufts University School of Medicine (Boston, MA) and Sorbonne Université (Paris, France) have demonstrated a remarkable 20-year clinical and serological remission in patients using a defined protocol of intravenous immunoglobulin (IVIg) therapy.
  • Twenty-one patients with confirmed PV received IVIg therapy according to a specific protocol.
  • This long-term remission suggests that IVIg may help restore immune balance and tolerance in PV patients.
  • The pioneering research, offering sustained remission for pemphigus vulgaris patients, highlights the considerable potential of IVIg therapy.

Jennifer Rider Appointed ConcertAI Head of Real-World Evidence Services

Retrieved on: 
Tuesday, January 30, 2024
Real-World Evidence, Abstract, Interview, Oncology, Research, AI, Clinical Cancer Research, Public, Flexner Report, FDA, Publication, Public health, Aetion, RCT, RWE, Harvard University, Epidemiology, MPH, Doctor of Science, Harvard Medical School, Drug development, Health, Doctor of Philosophy, University, University of Wisconsin–Madison, RWD

CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- ConcertAI, the leader in oncology Real-World Data (RWD) and AI SaaS Solutions and for healthcare and life sciences, today announced Jennifer Rider, ScD, MPH, as the leader of the company's Real-World Evidence Services, focusing on regulatory applications of RWD as part of registration trials, breakthrough designation solutions post-approval studies, and regulatory registries. 

Key Points: 
  • Dr. Rider has over 20 years of experience in cancer epidemiology and real-world evidence research.
  • She first joined ConcertAI in 2020, moving from there to lead Aetion's Oncology Center of Excellence.
  • "Real-world evidence has taken on a more formal role in regulatory decision-making with the FDA's formalization of their guidance late last year ," said Jeff Elton, PhD, CEO of ConcertAI.
  • To hear more from Jennifer directly, listen to her interview on the latest episode of The ConcertAI Podcast here .

Leading Veterinary Software Company Instinct Science Acquires VetMedux, Owner of Fast-Growing Clinician's Brief and Plumb’s Veterinary Drugs

Retrieved on: 
Monday, January 29, 2024
Patient, Hospital, Health, Software as a service, Doctor of Pharmacy, Science, Workflow, VMD, Acquisition, Doctor of Science, DVM, Workforce, Education, Veterinarian, Growth, Nursing

DOYLESTOWN, Pa. and TULSA, Okla., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Instinct Science, a leading software provider for veterinary hospitals, today announced that it has acquired VetMedux, a trusted education and point-of-care information company that owns Clinician's Brief and Plumb’s Veterinary Drugs.

Key Points: 
  • DOYLESTOWN, Pa. and TULSA, Okla., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Instinct Science, a leading software provider for veterinary hospitals, today announced that it has acquired VetMedux, a trusted education and point-of-care information company that owns Clinician's Brief and Plumb’s Veterinary Drugs.
  • Those tools will be bolstered by the addition of Clinician’s Brief and Plumb’s Veterinary Drugs, which consistently rank as the most essential information resources for industry professionals.
  • “Instinct is on an ambitious path to provide game-changing software tools to the veterinary caretakers of today and tomorrow,” said Caleb Frankel, VMD, Founder and CEO of Instinct.
  • Instinct powers many of the veterinary industry’s university teaching hospitals, internship and residency training centers, and multi-specialty/emergency advanced care practices.

Combination Therapy and Precision Medicine Spotlighted as the Gold Standard for the Next Generation of Alzheimer's Treatments in the Journal of Prevention of Alzheimer's Disease (JPAD)

Retrieved on: 
Tuesday, January 16, 2024
Fillit, Entrepreneurship, Drug, School, Patient, Biology, Risk, Reno 1868 FC, Science, Research, MD, Oxidative stress, Next Generation, Biomarker, Drug development, Internal medicine, University, Geriatrics, Cancer, Ageing, Neuroprotection, UNLV, Journal, Karolinska Institute, Doctor of Science, Medicine, Autophagy, Therapy, Doctor of Philosophy, Syndrome, IHU, Dementia, Pharmaceutical industry

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The Journal of Prevention of Alzheimer's Disease (JPAD) with the support of the Alzheimer's Drug Discovery Foundation (ADDF) recently published a comprehensive issue, "The Biology of Aging: Leading The Next Generation of Alzheimer's Drug Development With a Geroscience Focus," which supports the consensus that combination therapy and precision medicine are the future of Alzheimer's treatment. This landmark publication arrives at a critical time in the Alzheimer's research field following significant drug breakthroughs of anti-amyloid therapies and the emergence of the biology of aging as the leading approach for drug development. This issue emphasizes the need to advance new therapies that target the underlying biology of the disease while also offering a roadmap for the next generation of Alzheimer's therapies.

Key Points: 
  • This issue emphasizes the need to advance new therapies that target the underlying biology of the disease while also offering a roadmap for the next generation of Alzheimer's therapies.
  • Each of these novel targets introduces a new and much-needed multi-pronged approach for developing Alzheimer's treatments, which can complement anti-amyloid drugs on the market.
  • The development of future therapies will enhance our growing understanding of the disease and how the various pathways interact to affect the disease state."
  • "This is a noteworthy achievement, as the publication will serve as the first extensive roadmap of non-amyloid pathways with the potential to address the complexity of Alzheimer's disease."

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

Retrieved on: 
Tuesday, January 9, 2024
Venetoclax, Patient, CRC, MRD, EFS, MD, OS, Acute myeloid leukemia, SLS, COVID, PD, Standard of care, Azacitidine, Food, COVID 19, Disease, Safety, Doctor of Science, Sepsis, Fast Track, FDA, AML, Treatment, CDK9, Pharmaceutical industry

NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to SLS009 (formerly GFH009), its novel and highly selective CDK9 inhibitor, for the treatment of relapsed/refractory (r/r) acute myeloid leukemia (AML). The Fast Track Designation is intended to facilitate the development and review of drugs to treat serious conditions and fill an unmet medical need.

Key Points: 
  • The Fast Track Designation is intended to facilitate the development and review of drugs to treat serious conditions and fill an unmet medical need.
  • Importantly, as of the last follow-up, eight of the nine patients enrolled in the 45 mg cohort were alive.
  • The first patient enrolled in the study achieved a complete response (CR) and continues on study in the seventh month with full peripheral blood recovery.
  • Eight patients (89%) remain alive (one patient succumbed to sepsis having previously contracted COVID 19) and six continue treatment.

SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones

Retrieved on: 
Wednesday, January 3, 2024
Mesothelioma, Therapeutic index, Doctor of Science, Food, Survival, Lymphoma, Bone marrow, BLA, Ovarian cancer, GPS, MRD, FDA, Type, CMC, CR2, MD, Nivolumab, WT1, Clinical trial, SLS, Acute myeloid leukemia, Patient, Safety, PTCL, AML, Pembrolizumab, Pharmaceutical industry

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and will host a corporate webinar at 8:30 am ET.

Key Points: 
  • “2023 was a very productive year for SELLAS,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS.
  • Dr. Stergiou continued: “We hope to build on this excellent progress and look forward to multiple clinical milestones that have the potential to create significant value for our shareholders.
  • Meaningful cell killing activity, defined as ≥50% reduction in blasts in the bone marrow, was observed at several dose levels.
  • This study is fully funded by the Company’s partner for SLS009, GenFleet Therapeutics (Shanghai), Inc. and is being conducted in China.

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Retrieved on: 
Thursday, December 21, 2023
Marketing, Doctor of Science, Food, FDA, CDK9, HDAC, ODD, MD, Therapy, SLS, Belinostat, Patient, Acute myeloid leukemia, Safety, Diagnosis, PTCL, Lymphoma, Bone marrow, Pharmaceutical industry

NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SLS009, the Company’s novel and highly selective CDK9 inhibitor, for the treatment of relapsed/refractory (r/r) Peripheral T-cell Lymphomas (PTCL).

Key Points: 
  • “We are delighted to announce the FDA’s granting of ODD for SLS009, marking another significant milestone following the recent Fast Track Designation by the FDA for PTCL,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS.
  • “In the recently completed dose-escalation portion of the Phase 1 trial in r/r hematological malignancies, SLS009 achieved clinical responses in PTCL including two patients reaching complete response.
  • The patients who achieved complete response in the SLS009 study were previously treated with regimens containing an HDAC inhibitor.
  • These benefits include assistance in the drug development process, tax credits for qualified clinical costs, exemptions from certain FDA fees and seven years of marketing exclusivity.

SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia

Retrieved on: 
Thursday, December 14, 2023
Patient, Doctor of Science, Food, Sepsis, DLT, COVID 19, CDK9, EFS, MD, PD, CRC, SLS, Monitoring, COVID, Azacitidine, Venetoclax, Safety, Acute myeloid leukemia, OS, AML, Enrollment

NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the first patients have been enrolled in the 60 mg dose cohort in its ongoing Phase 2a clinical trial of its novel and highly selective CDK9 inhibitor, SLS009, in combination with venetoclax and azacitidine (aza/ven) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) who did not respond or stopped responding to venetoclax-based therapies.

Key Points: 
  • A total of nine patients have been enrolled at the 45 mg safety dose level.
  • Eight patients remain alive (one patient succumbed to sepsis having previously contracted COVID 19) and six continue treatment.
  • The first enrolled patient achieved a complete response and is currently in the seventh month of treatment and the second enrolled patient is in the sixth month of treatment.
  • In the 60 mg dose cohort, patients will be randomized to one of two groups, 60 mg flat (fixed) dose once per week and 30 mg fixed dose two times per week.

SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET

Retrieved on: 
Wednesday, December 13, 2023
School, Doctor of Science, GPS, MD Anderson Cancer Center, MD, SLS, Patient, Acute myeloid leukemia, University, Medical school, Pharmaceutical industry

NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host a corporate update webinar on Wednesday, January 3, 2024, at 8:30 a.m. Eastern Time.

Key Points: 
  • NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host a corporate update webinar on Wednesday, January 3, 2024, at 8:30 a.m. Eastern Time.
  • Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will discuss the Company’s achievements in 2023 and provide an outlook for 2024.
  • Dr. Stergiou will be joined by two key opinion leaders and principal investigators who will discuss the Phase 3 registrational REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia and the clinical program for SLS009, the Company’s CDK9 inhibitor:
    Dr. Panagiotis Tsirigotis, Professor of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
    Dr. Tapan Kadia, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas
    To access the webinar, please use the following information: